Physiological Indirect Effect Modeling of the Antilipolytic Effects of Adenosine A1-receptor Agonists

Overview

Journal J Pharmacokinet Biopharm

Specialty Pharmacology

Date 1998 Aug 11

PMID 9697077

Citations 5

Authors

E A van Schaick

H J de Greef

A P IJzerman

M Danhof

Affiliations

Soon will be listed here.

Abstract

The relationship between blood concentrations of the adenosine A1-receptor agonist N6-(p-sulfophenyl) adenosine (SPA) and its effect on both plasma nonesterified fatty acid (NEFA) and glycerol release was described on the basis of an integrated pharmacokinetic-pharmacodynamic model. An indirect response model rather than a hypothetical "link" model was used to account for the delayed response. For that purpose an empirical solution to the differential equation describing the physiological indirect response model is presented. The model-estimated rate constant for the output of the glycerol response was compared to the elimination rate constant after exogenous administration of glycerol. In a crossover designed study, chronically cannulated male Wistar rats were subjected to either SPA administration (120 microgram/kg for 15 min) for measurement of the effects on glycerol, or glycerol administration for determination of glycerol pharmacokinetics. Glycerol pharmacokinetics was determined in the presence of a stable level of SPA (171 +/- 6 ng/ml) to suppress endogenous glycerol levels completely. The indirect response model adequately described the relationship between SPA concentrations and plasma glycerol levels. The PD parameter estimates for EC50, EMAX, and Hill factor were 23 +/- 2 ng/ml, 74 +/- 3% (change from baseline), and 3.3 +/- 0.5, respectively. These values were not different from those obtained when analyzing the data on basis of the differential equation directly. Furthermore, the EC50 values for the reduction in glycerol or NEFA levels were identical (23 +/- 2 and 21 +/- 3 ng/ml, respectively) indicating that both PD endpoints reflect the same physiological process. The concentration-time profile after administration of glycerol could be described best on the basis of a biexponential function. The value for kout in the PK/PD model (0.19 +/- 0.03 min-1) corresponded very well to the terminal elimination rate constant determined after i.v. administration of glycerol (0.25 +/- 0.03 min-1). In conclusion, the antilipolytic effects of adenosine A1-receptor agonists can be described by the indirect suppression model. The rate constant describing the delay between concentration and glycerol effect was shown to be a true reflection of the removal of glycerol.

Citing Articles

Pharmacokinetic-pharmacodynamic model of newly developed dexibuprofen sustained release formulations.

Muralidharan S ISRN Pharm. 2013; 2012:451481.

PMID: 23316393 PMC: 3534360. DOI: 10.5402/2012/451481.

Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats.

Fang J, DuBois D, He Y, Almon R, Jusko W J Pharmacokinet Pharmacodyn. 2011; 38(3):293-316.

PMID: 21394487 PMC: 3407886. DOI: 10.1007/s10928-011-9194-4.

Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.

Krzyzanski W, Jusko W J Pharmacokinet Pharmacodyn. 2001; 28(1):57-78.

PMID: 11253614 DOI: 10.1023/a:1011517718990.

Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.

Cleton A, de Greef H, Edelbroek P, Voskuyl R, Danhof M J Pharmacokinet Biopharm. 2000; 27(3):301-23.

PMID: 10728492 DOI: 10.1023/a:1020999114109.

Note: caution in use of empirical equations for pharmacodynamic indirect response models.

Krzyzanski W, Jusko W J Pharmacokinet Biopharm. 1999; 26(6):735-41.

PMID: 10485083 DOI: 10.1023/a:1020707208521.

References

Londos C, Honnor R, Dhillon G . cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators. J Biol Chem. 1985; 260(28):15139-45. View

Randle P, Garland P, Hales C, Newsholme E . The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1(7285):785-9. DOI: 10.1016/s0140-6736(63)91500-9. View

Schwabe U, Ebert R, Erbler H . Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3',5'-AMP levels and lipolysis. Naunyn Schmiedebergs Arch Pharmacol. 1973; 276(2):133-48. DOI: 10.1007/BF00501186. View

Collis M, Hourani S . Adenosine receptor subtypes. Trends Pharmacol Sci. 1993; 14(10):360-6. DOI: 10.1016/0165-6147(93)90094-z. View

Jusko W, Ko H . Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994; 56(4):406-19. DOI: 10.1038/clpt.1994.155. View

Nichols A, DAmbrosio R, Pyszczynski N, Jusko W . Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. J Pharmacol Exp Ther. 1989; 250(3):963-70. View

Jacobson K, Nikodijevic O, Ji X, Berkich D, Eveleth D, Dean R . Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. J Med Chem. 1992; 35(22):4143-9. PMC: 3420980. DOI: 10.1021/jm00100a020. View

Yamashita S, Ludwig E, MIDDLETON Jr E, Jusko W . Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther. 1991; 49(5):558-70. DOI: 10.1038/clpt.1991.66. View

Dayneka N, Garg V, Jusko W . Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993; 21(4):457-78. PMC: 4207304. DOI: 10.1007/BF01061691. View

10.

McGarry J . What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 1992; 258(5083):766-70. DOI: 10.1126/science.1439783. View

11.

Reaven G, Chen Y . Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med. 1988; 85(5A):106-12. DOI: 10.1016/0002-9343(88)90402-0. View

12.

Reaven G, Chang H, Ho H, Jeng C, Hoffman B . Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol. 1988; 254(1 Pt 1):E23-30. DOI: 10.1152/ajpendo.1988.254.1.E23. View

13.

Ackermann R, Bassler K, Wagner K . [Glycerin: utilization, turnover capacity and biokinetic data in intravenous administration in the rat]. Infusionsther Klin Ernahr. 1975; 2(1):9-15. View

14.

Yamaoka K, Nakagawa T, Uno T . Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978; 6(2):165-75. DOI: 10.1007/BF01117450. View

15.

Nichols A, Jusko W . Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. J Pharmacokinet Biopharm. 1990; 18(3):189-208. DOI: 10.1007/BF01062199. View

16.

Gardner C, Twissell D, Coates J, Strong P . The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur J Pharmacol. 1994; 257(1-2):117-21. DOI: 10.1016/0014-2999(94)90702-1. View

17.

Jacobson K, van Galen P, Williams M . Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem. 1992; 35(3):407-22. PMC: 3476067. DOI: 10.1021/jm00081a001. View

18.

Strong P, Anderson R, Coates J, Ellis F, Evans B, Gurden M . Suppression of non-esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Clin Sci (Lond). 1993; 84(6):663-9. DOI: 10.1042/cs0840663. View

19.

van Schaick E, de Greef H, Langemeijer M, Sheehan M, IJzerman A, Danhof M . Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats. Br J Pharmacol. 1997; 122(3):525-33. PMC: 1564970. DOI: 10.1038/sj.bjp.0701412. View

20.

Peck C, Barr W, Benet L, Collins J, Desjardins R, Furst D . Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther. 1992; 51(4):465-73. DOI: 10.1038/clpt.1992.47. View